<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01589497</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5307</org_study_id>
    <secondary_id>1U01AI068636</secondary_id>
    <nct_id>NCT01589497</nct_id>
  </id_info>
  <brief_title>Essentiality of INH in TB Therapy</brief_title>
  <official_title>Essentiality of Isoniazid in Tuberculosis Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis (TB) disease is caused by bacteria that have infected the lung. TB bacteria are
      very small living agents that are spread by coughing and can be killed by taking TB drugs. To
      kill these TB bacteria TB patients have to take a combination of four drugs for 2 months and
      then two drugs for a further 4 months. During the first 2 months patients take rifampicin,
      isoniazid, ethambutol, and pyrazinamide. After that patients take only isoniazid and
      rifampicin for a further 4 months, making a total of 6 months therapy.

      In A5307 the investigators wanted to test a new combination of drugs to see if the
      investigators could treat TB faster in the future.

      Studies in animals have suggested that one of the four drugs, isoniazid, only works for a few
      days and may not be needed after the first two doses of TB treatment to kill the TB bacteria.
      After that its effects wear off to the point that it may even interfere with the other drugs.
      The investigators wanted to see if stopping isoniazid early, or using moxifloxacin, a
      different drug, instead could treat TB faster. This study was the first time that this type
      of regimen without isoniazid had been tested in humans. If the investigators could show that
      isoniazid stops working after a few days, the investigators could then try to see if they
      could possibly make a better tuberculosis treatment in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase IIa open label, randomized clinical trial comparing the early bactericidal
      activity (EBA) of four anti-tuberculosis regimens. Participants with acid fast bacilli (AFB)
      smear-positive pulmonary tuberculosis were hospitalized from screening through Day 15 of the
      study, during which time, sputum, blood, and urine were collected. Participants returned to
      the clinic on Day 28 for the final visit. The study duration was 29 days.

      The purpose of the study was to estimate the primary outcome within each study arm and the
      study was not designed for between arm comparisons.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 30, 2015</start_date>
  <completion_date type="Actual">February 10, 2016</completion_date>
  <primary_completion_date type="Actual">January 28, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14</measure>
    <time_frame>Pre-entry, Day 0 and Day 14</time_frame>
    <description>The daily decrease was calculated as follows:
EBA0-14(CFU)= [baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) - log10 CFU/mL at day 14]/14. For a CFU/ml count of 0, the log10 CFU/mL was set to 0.
No formal statistical testing was conducted to compare the arms. Please refer to the explanation in the Protocol Section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 14</measure>
    <time_frame>Pre-entry, Day 0 and Day 14</time_frame>
    <description>The daily change in TTP was calculated as follows:
EBA0-14(TTP) = [baseline TTP (mean of TTP at pre-entry and day 0) - TTP at day 14]/14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Change in log10 Transformed Colony-forming Unit (CFU) Counts Per mL Sputum From Baseline (Study Treatment Initiation) to Day 2</measure>
    <time_frame>Pre-entry, Day 0 and Day 2</time_frame>
    <description>The daily change in log10 CFU/mL sputum was calculated as follows:
EBA0-2(CFU) = (baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) - log10 CFU/mL at day 2)/2.
For a CFU/mL count of 0, the log10 CFU/mL was set to 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Change in log10 Colony-forming Unit (CFU) Counts Per mL Sputum From Day 2 to Day 14</measure>
    <time_frame>Day 2 and day 14</time_frame>
    <description>The daily change in log10 CFU/mL sputum was calculated as follows:
EBA2-14(CFU) = (log10 CFU/mL at day 2 - log10 CFU/mL at day 14)/12.
For a CFU/mL count of 0, the log10 CFU/mL was set to 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 2</measure>
    <time_frame>Pre-entry, Day 0 and Day 2</time_frame>
    <description>The daily change in TTP was calculated as follows:
EBA0-2(TTP) = (baseline TTP (mean of TTP at pre-entry and day 0) - TTP at day 2)/2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Change in Time to Positivity (TTP) From Day 2 to Day 14</measure>
    <time_frame>Day 2 and Day 14</time_frame>
    <description>The daily change in TTP was calculated as follows:
EBA2-14(TTP) = (TTP at day 2 - TTP at day 14)/12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Log10 Transformed Colony-forming Unit (CFU) Count Per mL From Sputum Samples at Baseline and Day 14</measure>
    <time_frame>Pre-entry, Day 0 and Day 14</time_frame>
    <description>The log10 CFU count per mL from sputum samples processed by standard method or decontaminated method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Time to Positivity (TTP) and log10 Transformed Colony-forming Unit (CFU) Counts Per mL</measure>
    <time_frame>Pre-entry, Day 0, Day 1, Day 2, Day 3, Day 5, Day 7, Day 9, Day 11 and Day 14</time_frame>
    <description>Pearson correlation coefficient was used to examine the correlation between TTP and log10 CFU among all qualified samples obtained on study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter (PK) Area Under the Concentration-time Curve (AUC0-24hour) for Rifampicin (RIF)</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14</time_frame>
    <description>Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUCs) of Rifampicin from 0 to 24 hours obtained at Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rifampicin PK Parameter Clearance (CL/F)</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14</time_frame>
    <description>Rifampicin PK parameter Clearance (CL/F) obtained Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rifampicin PK Parameter Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14</time_frame>
    <description>Rifampicin PK parameter Parameter Maximum Plasma Concentration (Cmax) obtained Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rifampicin PK Parameter Last Concentration (CLast)</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14</time_frame>
    <description>Rifampicin (RIF) PK parameter Last Concentration (CLast) obtained Day 1 and Day 14. The lower limit of quantification of the assay (LLOQ) for RIF was 40 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 20 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24hour for Isoniazid (INH) at Day 1</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1</time_frame>
    <description>PK AUCs of Isoniazid (INH) from 0 to 24 hours obtained at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isoniazid PK Parameter CL/F at Day 1</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1</time_frame>
    <description>Isoniazid PK parameter CL/F obtained Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isoniazid PK Parameter Cmax at Day 1</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1</time_frame>
    <description>Isoniazid PK parameter Cmax obtained Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isoniazid PK Parameter CLast at Day 1</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1</time_frame>
    <description>Isoniazid (INH) PK parameter CLast obtained Day 1. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24hour for Isoniazid at Day 14</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14</time_frame>
    <description>PK AUCs of Isoniazid from 0 to 24 hours obtained at Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isoniazid PK Parameter CL/F at Day 14</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14</time_frame>
    <description>Isoniazid PK parameter CL/F obtained Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isoniazid PK Parameter Cmax at Day 14</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14</time_frame>
    <description>Isoniazid PK parameter Cmax obtained Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isoniazid PK Parameter CLast at Day 14</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14</time_frame>
    <description>Isoniazid (INH) PK parameter CLast obtained Day 14. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24hour for Pyrazinamide (PZA)</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14</time_frame>
    <description>PK AUCs of Pyrazinamide (PZA) from 0 to 24 hours obtained at Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pyrazinamide PK Parameter CL/F</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14</time_frame>
    <description>Pyrazinamide PK parameter CL/F obtained Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pyrazinamide PK Parameter Cmax</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14</time_frame>
    <description>Pyrazinamide PK parameter Cmax obtained Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pyrazinamide PK Parameter CLast</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14</time_frame>
    <description>Pyrazinamide PK parameter CLast obtained Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24hour for Ethambutol (EMB)</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14</time_frame>
    <description>PK AUCs of Ethambutol (EMB) from 0 to 24 hours obtained at Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethambutol PK Parameter CL/F</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14</time_frame>
    <description>Ethambutol PK parameter CL/F obtained Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethambutol PK Parameter Cmax</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14</time_frame>
    <description>Ethambutol PK parameter Cmax obtained Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ethambutol PK Parameter CLast</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14</time_frame>
    <description>Ethambutol PK parameter CLast obtained Day 1 and Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24hour for Moxifloxacin (Mox) at Day 14</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14</time_frame>
    <description>PK AUCs of Moxiflozacin (Mox) from 0 to 24 hours obtained at Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moxifloxacin PK Parameter CL/F at Day 14</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14</time_frame>
    <description>Moxifloxacin PK parameter CL/F obtained Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moxifloxacin PK Parameter Cmax at Day 14</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14</time_frame>
    <description>Moxifloxacin PK parameter Cmax obtained Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moxifloxacin PK Parameter CLast at Day 14</measure>
    <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14</time_frame>
    <description>Moxifloxacin PK parameter CLast obtained Day 14</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>RHZE-RHZE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were administered rifampin-isoniazid-pyrazinamide-ethambutol (RHZE) from Day 1 to Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RHZE-RZE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were administered RHZE from Day 1 to Day 2, then rifampin-pyrazinamide-ethambutol (RZE) from Day 3 to Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RHZE-RMZE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were administered RHZE Day 1 to Day 2 and rifampin-moxifloxacin-pyrazinamide-ethambutol (RMZE) from Day 3 to Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RZE-RZE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants were administered only RZE from Day 1 through Day 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Participants with body weight &lt;/= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight &gt;50kg were administered one 600 mg tablet orally once daily.</description>
    <arm_group_label>RHZE-RHZE</arm_group_label>
    <arm_group_label>RHZE-RZE</arm_group_label>
    <arm_group_label>RHZE-RMZE</arm_group_label>
    <arm_group_label>RZE-RZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Participants were administered three 100 mg tablets or one 300 mg tablet once daily.</description>
    <arm_group_label>RHZE-RHZE</arm_group_label>
    <arm_group_label>RHZE-RZE</arm_group_label>
    <arm_group_label>RHZE-RMZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.</description>
    <arm_group_label>RHZE-RHZE</arm_group_label>
    <arm_group_label>RHZE-RZE</arm_group_label>
    <arm_group_label>RHZE-RMZE</arm_group_label>
    <arm_group_label>RZE-RZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <description>Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.</description>
    <arm_group_label>RHZE-RHZE</arm_group_label>
    <arm_group_label>RHZE-RZE</arm_group_label>
    <arm_group_label>RHZE-RMZE</arm_group_label>
    <arm_group_label>RZE-RZE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Participants were administered one 400 mg tablet orally once a day.</description>
    <arm_group_label>RHZE-RMZE</arm_group_label>
    <other_name>Avelon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Absence of HIV-1 infection within 30 days prior to study entry OR

          -  HIV-1 infection

          -  Sputum positive for acid fast bacilli (AFB) by smear-microscopy ≥1+ on the WHO/IUALTD
             scale within 1 day prior to study entry.

          -  Isoniazid and rifampin sensitivity, based on Hain GenoType MTBDR Plus assay performed
             within 7 days prior to study entry.

          -  Body weight: 40 kg to 90 kg, inclusive

          -  Age ≥ 18 years at study entry.

          -  Certain laboratory values, as defined in the protocol, obtained within 30 days prior
             to entry

          -  For HIV-positive candidates only: CD4+ cell count of &gt; 200 cells/mm^3, determined
             within 7 days prior to study entry at a DAIDS approved laboratory.

          -  For females of reproductive potential, negative serum or urine pregnancy test within 7
             days prior to entry.

          -  Female participants who are participating in sexual activity that could lead to
             pregnancy must agree to use one reliable non-hormonal form of contraceptive (ie,
             condoms, with a spermicidal agent; a diaphragm, or cervical cap with spermicide; or an
             IUD) while receiving study medications.

          -  Radiographic findings consistent with pulmonary TB from a chest x-ray performed within
             14 days prior to entry.

          -  Ability and willingness of study candidate or legal guardian/representative to provide
             informed consent.

          -  Willingness to be hospitalized for approximately 3 weeks.

          -  Ability to provide at least 10mL of sputum during an overnight collection prior to
             study entry.

        NOTE: Candidates who do not produce an overnight sputum sample of sufficient quality and
        quantity will be considered screen failures. However, if a candidate's failure to produce
        sufficient sputum appears to be due to poor technique rather than low volume of sputum
        production, this evaluation may be repeated.

        Exclusion Criteria:

          -  Receipt of INH prophylaxis or any tuberculosis therapy within 7 days prior to study
             entry or for more than 7 cumulative days in the last 6 months, or receipt of any
             fluoroquinolone in the 1 month prior to entry.

          -  Currently on anti-retroviral treatment (ART), has been on ART within 30 days, or is
             expected to initiate ART within 2 weeks after study entry.

          -  Breastfeeding.

          -  Known intolerance to any of the study drugs.

          -  Resistance to rifampicin determined by GeneXpert within 7 days prior to study entry.

          -  Known history of resistance to isoniazid or rifampin or known close exposure (i.e.,
             household exposure) to someone with MDR TB or known study candidate default on
             previous TB treatment (ie, the study candidate was diagnosed with TB, started TB
             treatment but did not complete that treatment).

          -  Known allergy to any fluoroquinolone antibiotic.

          -  History of prolonged QT syndrome or a QTc of &gt; 450 ms (using Fridericia's
             correction)..

          -  Current or planned therapy with quinidine, procainamide, amiodarone, sotalol, or
             ziprasidone during the 2 weeks of on-study tuberculosis treatment.

          -  Current or prior diagnosis of pulmonary silicosis.

          -  Advanced disease as defined by Karnofsky score ≤ 70 at screening.

          -  Any of the following current comorbidities, complications, or underlying medical
             conditions:

               -  poorly controlled diabetes, as determined by the site investigator

               -  currently uncontrolled hypertension (ie, requiring acute medical treatment or
                  immediate hospitalization)

               -  miliary TB

               -  neurological TB (including TB of the spine, TB meningitis)

               -  peripheral neuropathy ≥ Grade 2 according to the December 2004 (Clarification,
                  August 2009) Division of AIDS (DAIDS) Toxicity Table, within 90 days prior to
                  study entry

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.

          -  Estimated overnight sputum production of &lt; 10 mL.

          -  Requirement for concomitant medications that may potentially interact with study
             drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Bishai, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins Center for TB Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Diacon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>TASK Applied Science CRS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cape Town Lung Institute (UCTLI) CRS (31792)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7705</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TASK Applied Science CRS (31718)</name>
      <address>
        <city>Bellville</city>
        <zip>7531</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 (Clarification, August 2009).</citation>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <results_first_submitted>January 24, 2017</results_first_submitted>
  <results_first_submitted_qc>March 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited at two AIDS Clinical Trials Units in South Africa. Recruitment occurred between June 30, 2015 (date of first participant was randomized) and January 13, 2016 (date of last participant was randomized).</recruitment_details>
      <pre_assignment_details>69 were randomized 1:1:1:1 to 4 treatment arms. Among the 69 participants, 63 with qualified samples were included in the primary and secondary analyses including PK analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RHZE-RHZE</title>
          <description>Participants were administered RHZE from Day 1 to Day 14. Rifampicin: Participants with body weight &lt;/= 50kg were administered one 450 mg tablet orally once daily; with body weight &gt;50kg were administered one 600 mg tablet orally once daily.
Isoniazid: Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
Pyrazinamide: Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily; with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily; with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
Ethambutol: Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily; with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily; with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.</description>
        </group>
        <group group_id="P2">
          <title>RHZE-RZE</title>
          <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.
Rifampicin: Participants with body weight &lt;/= 50kg were administered one 450 mg tablet orally once daily; with body weight &gt;50kg were administered one 600 mg tablet orally once daily.
Isoniazid: Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
Pyrazinamide: Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily; with body weight of 56-75 kg were administered three 500 mg tablets orally once daily; with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
Ethambutol: Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily; with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily; with a body weight of 76-90 kg were administered four 400 mg tablets orally once</description>
        </group>
        <group group_id="P3">
          <title>RHZE-RMZE</title>
          <description>Participants were administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.
Rifampicin: Participants with body weight &lt;/= 50kg were administered one 450 mg tablet orally once daily; with body weight &gt;50kg were administered one 600 mg tablet orally once daily.
Isoniazid: Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
Pyrazinamide: Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily; with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily; with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
Ethambutol: Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily; with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily; with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
Moxifloxacin: one 400 mg tablet orally once a day.</description>
        </group>
        <group group_id="P4">
          <title>RZE-RZE</title>
          <description>Participants were administered only RZE from Day 1 through Day 14. Rifampicin: Participants with body weight &lt;/= 50kg were administered one 450 mg tablet orally once daily; with body weight &gt;50kg were administered one 600 mg tablet orally once daily.
Pyrazinamide: Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily; with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily; with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
Ethambutol: Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily; with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily; with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17">1 participant who completed study but had insufficient sputum volume was excluded from the analyses</participants>
                <participants group_id="P2" count="16">1 participant who completed study but had insufficient sputum volume was excluded from the analyses</participants>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pre-entry overnight sputum&lt; 10ML</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat: All enrolled 69 participants were included in the baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>RHZE-RHZE</title>
          <description>Participants were administered RHZE from Day 1 to Day 14.</description>
        </group>
        <group group_id="B2">
          <title>RHZE-RZE</title>
          <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
        </group>
        <group group_id="B3">
          <title>RHZE-RMZE</title>
          <description>Participants were administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
        </group>
        <group group_id="B4">
          <title>RZE-RZE</title>
          <description>Participants were administered only RZE from Day 1 through Day 14.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" lower_limit="22" upper_limit="33"/>
                    <measurement group_id="B2" value="31" lower_limit="30" upper_limit="35"/>
                    <measurement group_id="B3" value="33.5" lower_limit="25.5" upper_limit="43"/>
                    <measurement group_id="B4" value="32" lower_limit="21" upper_limit="44"/>
                    <measurement group_id="B5" value="31" lower_limit="24" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;20</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>20-29</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30-39</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>40-49</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>50-59</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky score</title>
          <description>The karnofsky score was determined according to karnofsky performance scale. The scale ranged from 0 to 100, by 10. A higher value represents a better outcome.</description>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="B2" value="90" lower_limit="80" upper_limit="90"/>
                    <measurement group_id="B3" value="90" lower_limit="80" upper_limit="90"/>
                    <measurement group_id="B4" value="90" lower_limit="80" upper_limit="90"/>
                    <measurement group_id="B5" value="90" lower_limit="80" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.5" lower_limit="17.5" upper_limit="20.9"/>
                    <measurement group_id="B2" value="19.4" lower_limit="17.5" upper_limit="20.4"/>
                    <measurement group_id="B3" value="19.8" lower_limit="17.7" upper_limit="22.7"/>
                    <measurement group_id="B4" value="18.7" lower_limit="16.8" upper_limit="20.4"/>
                    <measurement group_id="B5" value="18.9" lower_limit="17.5" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>HIV negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14</title>
        <description>The daily decrease was calculated as follows:
EBA0-14(CFU)= [baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) – log10 CFU/mL at day 14]/14. For a CFU/ml count of 0, the log10 CFU/mL was set to 0.
No formal statistical testing was conducted to compare the arms. Please refer to the explanation in the Protocol Section.</description>
        <time_frame>Pre-entry, Day 0 and Day 14</time_frame>
        <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants were administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Decrease in log10 Transformed Colony-forming Unit (CFU) Counts Per ml Sputum From Baseline (Study Treatment Initiation) to Day 14</title>
          <description>The daily decrease was calculated as follows:
EBA0-14(CFU)= [baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) – log10 CFU/mL at day 14]/14. For a CFU/ml count of 0, the log10 CFU/mL was set to 0.
No formal statistical testing was conducted to compare the arms. Please refer to the explanation in the Protocol Section.</description>
          <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
          <units>log10 CFU/ mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.134" lower_limit="0.078" upper_limit="0.167"/>
                    <measurement group_id="O2" value="0.096" lower_limit="0.028" upper_limit="0.211"/>
                    <measurement group_id="O3" value="0.136" lower_limit="0.090" upper_limit="0.169"/>
                    <measurement group_id="O4" value="0.119" lower_limit="0.050" upper_limit="0.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 14</title>
        <description>The daily change in TTP was calculated as follows:
EBA0-14(TTP) = [baseline TTP (mean of TTP at pre-entry and day 0) – TTP at day 14]/14.</description>
        <time_frame>Pre-entry, Day 0 and Day 14</time_frame>
        <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants were administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 14</title>
          <description>The daily change in TTP was calculated as follows:
EBA0-14(TTP) = [baseline TTP (mean of TTP at pre-entry and day 0) – TTP at day 14]/14.</description>
          <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" lower_limit="-17" upper_limit="-9"/>
                    <measurement group_id="O2" value="-12" lower_limit="-16" upper_limit="-8"/>
                    <measurement group_id="O3" value="-13" lower_limit="-17" upper_limit="-10"/>
                    <measurement group_id="O4" value="-11" lower_limit="-14" upper_limit="-9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Change in log10 Transformed Colony-forming Unit (CFU) Counts Per mL Sputum From Baseline (Study Treatment Initiation) to Day 2</title>
        <description>The daily change in log10 CFU/mL sputum was calculated as follows:
EBA0-2(CFU) = (baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) - log10 CFU/mL at day 2)/2.
For a CFU/mL count of 0, the log10 CFU/mL was set to 0.</description>
        <time_frame>Pre-entry, Day 0 and Day 2</time_frame>
        <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants were administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Change in log10 Transformed Colony-forming Unit (CFU) Counts Per mL Sputum From Baseline (Study Treatment Initiation) to Day 2</title>
          <description>The daily change in log10 CFU/mL sputum was calculated as follows:
EBA0-2(CFU) = (baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) - log10 CFU/mL at day 2)/2.
For a CFU/mL count of 0, the log10 CFU/mL was set to 0.</description>
          <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
          <units>log10 CFU/ mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.255" lower_limit="-0.037" upper_limit="0.519"/>
                    <measurement group_id="O2" value="0.385" lower_limit="-0.050" upper_limit="0.475"/>
                    <measurement group_id="O3" value="0.111" lower_limit="0.001" upper_limit="0.409"/>
                    <measurement group_id="O4" value="0.034" lower_limit="-0.366" upper_limit="0.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Change in log10 Colony-forming Unit (CFU) Counts Per mL Sputum From Day 2 to Day 14</title>
        <description>The daily change in log10 CFU/mL sputum was calculated as follows:
EBA2-14(CFU) = (log10 CFU/mL at day 2 - log10 CFU/mL at day 14)/12.
For a CFU/mL count of 0, the log10 CFU/mL was set to 0.</description>
        <time_frame>Day 2 and day 14</time_frame>
        <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants were administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Change in log10 Colony-forming Unit (CFU) Counts Per mL Sputum From Day 2 to Day 14</title>
          <description>The daily change in log10 CFU/mL sputum was calculated as follows:
EBA2-14(CFU) = (log10 CFU/mL at day 2 - log10 CFU/mL at day 14)/12.
For a CFU/mL count of 0, the log10 CFU/mL was set to 0.</description>
          <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
          <units>log10 CFU/ mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" lower_limit="0.104" upper_limit="0.203"/>
                    <measurement group_id="O2" value="0.093" lower_limit="0.010" upper_limit="0.171"/>
                    <measurement group_id="O3" value="0.123" lower_limit="0.113" upper_limit="0.173"/>
                    <measurement group_id="O4" value="0.104" lower_limit="0.065" upper_limit="0.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 2</title>
        <description>The daily change in TTP was calculated as follows:
EBA0-2(TTP) = (baseline TTP (mean of TTP at pre-entry and day 0) - TTP at day 2)/2.</description>
        <time_frame>Pre-entry, Day 0 and Day 2</time_frame>
        <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants were administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Change in Time to Positivity (TTP) From Baseline (Study Treatment Initiation) to Day 2</title>
          <description>The daily change in TTP was calculated as follows:
EBA0-2(TTP) = (baseline TTP (mean of TTP at pre-entry and day 0) - TTP at day 2)/2.</description>
          <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31" lower_limit="-44" upper_limit="-22"/>
                    <measurement group_id="O2" value="-30" lower_limit="-44" upper_limit="-15"/>
                    <measurement group_id="O3" value="-29" lower_limit="-35" upper_limit="-18"/>
                    <measurement group_id="O4" value="-25" lower_limit="-28" upper_limit="-18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Change in Time to Positivity (TTP) From Day 2 to Day 14</title>
        <description>The daily change in TTP was calculated as follows:
EBA2-14(TTP) = (TTP at day 2 - TTP at day 14)/12.</description>
        <time_frame>Day 2 and Day 14</time_frame>
        <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Change in Time to Positivity (TTP) From Day 2 to Day 14</title>
          <description>The daily change in TTP was calculated as follows:
EBA2-14(TTP) = (TTP at day 2 - TTP at day 14)/12.</description>
          <population>Participants with qualified sputum samples who had results available at all time points specified in the time-frame</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" lower_limit="-12" upper_limit="-6"/>
                    <measurement group_id="O2" value="-9" lower_limit="-13" upper_limit="-6"/>
                    <measurement group_id="O3" value="-12" lower_limit="-14" upper_limit="-8"/>
                    <measurement group_id="O4" value="-9" lower_limit="-12" upper_limit="-7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Log10 Transformed Colony-forming Unit (CFU) Count Per mL From Sputum Samples at Baseline and Day 14</title>
        <description>The log10 CFU count per mL from sputum samples processed by standard method or decontaminated method.</description>
        <time_frame>Pre-entry, Day 0 and Day 14</time_frame>
        <population>Participants with qualified sputum samples who had results available at least one time point specified in the time-frame</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Processing Method</title>
            <description>The standard sputum processing method</description>
          </group>
          <group group_id="O2">
            <title>Decontaminated Processing Method</title>
            <description>The decontaminated sputum processing method</description>
          </group>
        </group_list>
        <measure>
          <title>Log10 Transformed Colony-forming Unit (CFU) Count Per mL From Sputum Samples at Baseline and Day 14</title>
          <description>The log10 CFU count per mL from sputum samples processed by standard method or decontaminated method.</description>
          <population>Participants with qualified sputum samples who had results available at least one time point specified in the time-frame</population>
          <units>log10 CFU/ mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-entry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.80" lower_limit="5.16" upper_limit="6.76"/>
                    <measurement group_id="O2" value="5.89" lower_limit="5.10" upper_limit="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" lower_limit="5.16" upper_limit="6.65"/>
                    <measurement group_id="O2" value="5.58" lower_limit="5.02" upper_limit="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" lower_limit="3.34" upper_limit="4.60"/>
                    <measurement group_id="O2" value="3.74" lower_limit="3.11" upper_limit="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Time to Positivity (TTP) and log10 Transformed Colony-forming Unit (CFU) Counts Per mL</title>
        <description>Pearson correlation coefficient was used to examine the correlation between TTP and log10 CFU among all qualified samples obtained on study</description>
        <time_frame>Pre-entry, Day 0, Day 1, Day 2, Day 3, Day 5, Day 7, Day 9, Day 11 and Day 14</time_frame>
        <population>Participants with qualified sputum samples who had results available at least one time point specified in the time-frame</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>Qualified samples from overall participants</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Time to Positivity (TTP) and log10 Transformed Colony-forming Unit (CFU) Counts Per mL</title>
          <description>Pearson correlation coefficient was used to examine the correlation between TTP and log10 CFU among all qualified samples obtained on study</description>
          <population>Participants with qualified sputum samples who had results available at least one time point specified in the time-frame</population>
          <units>correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter (PK) Area Under the Concentration-time Curve (AUC0-24hour) for Rifampicin (RIF)</title>
        <description>Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUCs) of Rifampicin from 0 to 24 hours obtained at Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter (PK) Area Under the Concentration-time Curve (AUC0-24hour) for Rifampicin (RIF)</title>
          <description>Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUCs) of Rifampicin from 0 to 24 hours obtained at Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis</population>
          <units>h*ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RIF AUC0-24hour at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37358.8" lower_limit="23946.7" upper_limit="70314.2"/>
                    <measurement group_id="O2" value="42062.6" lower_limit="23048.7" upper_limit="77672.3"/>
                    <measurement group_id="O3" value="51434.1" lower_limit="42018.3" upper_limit="69759.7"/>
                    <measurement group_id="O4" value="39294.0" lower_limit="21282.6" upper_limit="55823.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RIF AUC0-24hour at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31361.4" lower_limit="15709.9" upper_limit="42480.9"/>
                    <measurement group_id="O2" value="27161.7" lower_limit="14436.6" upper_limit="31522.2"/>
                    <measurement group_id="O3" value="26751.2" lower_limit="16603.9" upper_limit="32635.8"/>
                    <measurement group_id="O4" value="30521.0" lower_limit="20749.5" upper_limit="35307.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rifampicin PK Parameter Clearance (CL/F)</title>
        <description>Rifampicin PK parameter Clearance (CL/F) obtained Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Rifampicin PK Parameter Clearance (CL/F)</title>
          <description>Rifampicin PK parameter Clearance (CL/F) obtained Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis</population>
          <units>L/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RIF CL/F Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="8.3" upper_limit="20.1"/>
                    <measurement group_id="O2" value="12.5" lower_limit="7.7" upper_limit="26.0"/>
                    <measurement group_id="O3" value="10.5" lower_limit="7.2" upper_limit="14.3"/>
                    <measurement group_id="O4" value="14.3" lower_limit="9.2" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RIF CL/F Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="14.1" upper_limit="34.0"/>
                    <measurement group_id="O2" value="22.1" lower_limit="14.3" upper_limit="31.2"/>
                    <measurement group_id="O3" value="21.5" lower_limit="15.7" upper_limit="36.1"/>
                    <measurement group_id="O4" value="17.0" lower_limit="14.7" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rifampicin PK Parameter Maximum Plasma Concentration (Cmax)</title>
        <description>Rifampicin PK parameter Parameter Maximum Plasma Concentration (Cmax) obtained Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Rifampicin PK Parameter Maximum Plasma Concentration (Cmax)</title>
          <description>Rifampicin PK parameter Parameter Maximum Plasma Concentration (Cmax) obtained Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RIF Cmax at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5565" lower_limit="3600" upper_limit="7685"/>
                    <measurement group_id="O2" value="6060" lower_limit="3200" upper_limit="9550"/>
                    <measurement group_id="O3" value="8660" lower_limit="4520" upper_limit="10800"/>
                    <measurement group_id="O4" value="4880" lower_limit="3370" upper_limit="7740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RIF Cmax at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7145" lower_limit="3525" upper_limit="9055"/>
                    <measurement group_id="O2" value="6960" lower_limit="3930" upper_limit="9020"/>
                    <measurement group_id="O3" value="7370" lower_limit="4700" upper_limit="9580"/>
                    <measurement group_id="O4" value="8350" lower_limit="5390" upper_limit="8970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rifampicin PK Parameter Last Concentration (CLast)</title>
        <description>Rifampicin (RIF) PK parameter Last Concentration (CLast) obtained Day 1 and Day 14. The lower limit of quantification of the assay (LLOQ) for RIF was 40 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 20 ng/mL.</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Rifampicin PK Parameter Last Concentration (CLast)</title>
          <description>Rifampicin (RIF) PK parameter Last Concentration (CLast) obtained Day 1 and Day 14. The lower limit of quantification of the assay (LLOQ) for RIF was 40 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 20 ng/mL.</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RIF CLast at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" lower_limit="20.0" upper_limit="232.0"/>
                    <measurement group_id="O2" value="20" lower_limit="20" upper_limit="229"/>
                    <measurement group_id="O3" value="133" lower_limit="20" upper_limit="288"/>
                    <measurement group_id="O4" value="20" lower_limit="20" upper_limit="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RIF CLast at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="20" upper_limit="20"/>
                    <measurement group_id="O2" value="20" lower_limit="20" upper_limit="20"/>
                    <measurement group_id="O3" value="20" lower_limit="20" upper_limit="20"/>
                    <measurement group_id="O4" value="20" lower_limit="20" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24hour for Isoniazid (INH) at Day 1</title>
        <description>PK AUCs of Isoniazid (INH) from 0 to 24 hours obtained at Day 1</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24hour for Isoniazid (INH) at Day 1</title>
          <description>PK AUCs of Isoniazid (INH) from 0 to 24 hours obtained at Day 1</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
          <units>h*ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10725.8" lower_limit="6412.9" upper_limit="16492.5"/>
                    <measurement group_id="O2" value="7970.6" lower_limit="4594.4" upper_limit="16101.7"/>
                    <measurement group_id="O3" value="7165.1" lower_limit="4974.5" upper_limit="19045.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Isoniazid PK Parameter CL/F at Day 1</title>
        <description>Isoniazid PK parameter CL/F obtained Day 1</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Isoniazid PK Parameter CL/F at Day 1</title>
          <description>Isoniazid PK parameter CL/F obtained Day 1</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
          <units>L/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="18.3" upper_limit="49.6"/>
                    <measurement group_id="O2" value="37.6" lower_limit="18.6" upper_limit="65.3"/>
                    <measurement group_id="O3" value="41.9" lower_limit="21.0" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Isoniazid PK Parameter Cmax at Day 1</title>
        <description>Isoniazid PK parameter Cmax obtained Day 1</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Isoniazid PK Parameter Cmax at Day 1</title>
          <description>Isoniazid PK parameter Cmax obtained Day 1</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3165" lower_limit="2315" upper_limit="4060"/>
                    <measurement group_id="O2" value="2920" lower_limit="1530" upper_limit="3610"/>
                    <measurement group_id="O3" value="2760" lower_limit="1760" upper_limit="4030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Isoniazid PK Parameter CLast at Day 1</title>
        <description>Isoniazid (INH) PK parameter CLast obtained Day 1. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL.</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Isoniazid PK Parameter CLast at Day 1</title>
          <description>Isoniazid (INH) PK parameter CLast obtained Day 1. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL.</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="50" upper_limit="50"/>
                    <measurement group_id="O2" value="50" lower_limit="50" upper_limit="50"/>
                    <measurement group_id="O3" value="50" lower_limit="50" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24hour for Isoniazid at Day 14</title>
        <description>PK AUCs of Isoniazid from 0 to 24 hours obtained at Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RHZE-RZE and RHZE-RMZE arms did not receive INH from Day 3 through Day 14 and the participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24hour for Isoniazid at Day 14</title>
          <description>PK AUCs of Isoniazid from 0 to 24 hours obtained at Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RHZE-RZE and RHZE-RMZE arms did not receive INH from Day 3 through Day 14 and the participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
          <units>h*ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9797.2" lower_limit="6931.1" upper_limit="16355.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Isoniazid PK Parameter CL/F at Day 14</title>
        <description>Isoniazid PK parameter CL/F obtained Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RHZE-RZE and RHZE-RMZE arms did not receive INH from Day 3 through Day 14 and the participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Isoniazid PK Parameter CL/F at Day 14</title>
          <description>Isoniazid PK parameter CL/F obtained Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RHZE-RZE and RHZE-RMZE arms did not receive INH from Day 3 through Day 14 and the participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
          <units>L/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6" lower_limit="18.4" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Isoniazid PK Parameter Cmax at Day 14</title>
        <description>Isoniazid PK parameter Cmax obtained Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RHZE-RZE and RHZE-RMZE arms did not receive INH from Day 3 through Day 14 and the participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Isoniazid PK Parameter Cmax at Day 14</title>
          <description>Isoniazid PK parameter Cmax obtained Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RHZE-RZE and RHZE-RMZE arms did not receive INH from Day 3 through Day 14 and the participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3130" lower_limit="2485" upper_limit="3920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Isoniazid PK Parameter CLast at Day 14</title>
        <description>Isoniazid (INH) PK parameter CLast obtained Day 14. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL.</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RHZE-RZE and RHZE-RMZE arms did not receive INH from Day 3 through Day 14 and the participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Isoniazid PK Parameter CLast at Day 14</title>
          <description>Isoniazid (INH) PK parameter CLast obtained Day 14. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL.</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. The participants in the RHZE-RZE and RHZE-RMZE arms did not receive INH from Day 3 through Day 14 and the participants in the RZE-RZE arm did not receive INH from Day 1 through Day 14.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="50" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24hour for Pyrazinamide (PZA)</title>
        <description>PK AUCs of Pyrazinamide (PZA) from 0 to 24 hours obtained at Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24hour for Pyrazinamide (PZA)</title>
          <description>PK AUCs of Pyrazinamide (PZA) from 0 to 24 hours obtained at Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
          <units>h*ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PZA AUC0-24hour at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301214.5" lower_limit="243041.4" upper_limit="344110.0"/>
                    <measurement group_id="O2" value="255283.0" lower_limit="204379.9" upper_limit="349309.1"/>
                    <measurement group_id="O3" value="292078.2" lower_limit="249250.9" upper_limit="304794.0"/>
                    <measurement group_id="O4" value="272853.9" lower_limit="217158.6" upper_limit="314465.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PZA AUC0-24hour at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249879.1" lower_limit="202652.1" upper_limit="319071.7"/>
                    <measurement group_id="O2" value="201389.7" lower_limit="174896.2" upper_limit="280573.1"/>
                    <measurement group_id="O3" value="280071.0" lower_limit="221878.7" upper_limit="312248.4"/>
                    <measurement group_id="O4" value="252276.8" lower_limit="192061.9" upper_limit="307469.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pyrazinamide PK Parameter CL/F</title>
        <description>Pyrazinamide PK parameter CL/F obtained Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Pyrazinamide PK Parameter CL/F</title>
          <description>Pyrazinamide PK parameter CL/F obtained Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
          <units>L/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PZA CL/F Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.3" upper_limit="5.0"/>
                    <measurement group_id="O2" value="4.8" lower_limit="3.9" upper_limit="5.8"/>
                    <measurement group_id="O3" value="4.7" lower_limit="3.4" upper_limit="5.2"/>
                    <measurement group_id="O4" value="4.2" lower_limit="3.7" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PZA CL/F Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4.0" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.4" lower_limit="4.8" upper_limit="6.9"/>
                    <measurement group_id="O3" value="4.7" lower_limit="3.9" upper_limit="5.3"/>
                    <measurement group_id="O4" value="4.7" lower_limit="3.8" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pyrazinamide PK Parameter Cmax</title>
        <description>Pyrazinamide PK parameter Cmax obtained Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Pyrazinamide PK Parameter Cmax</title>
          <description>Pyrazinamide PK parameter Cmax obtained Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PZA Cmax at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27650" lower_limit="24400" upper_limit="36550"/>
                    <measurement group_id="O2" value="27000" lower_limit="20800" upper_limit="29100"/>
                    <measurement group_id="O3" value="28800" lower_limit="23900" upper_limit="32600"/>
                    <measurement group_id="O4" value="25800" lower_limit="24100" upper_limit="29000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PZA Cmax at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29300" lower_limit="24950" upper_limit="34350"/>
                    <measurement group_id="O2" value="27000" lower_limit="22900" upper_limit="31000"/>
                    <measurement group_id="O3" value="29300" lower_limit="25500" upper_limit="33900"/>
                    <measurement group_id="O4" value="28000" lower_limit="26300" upper_limit="31900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pyrazinamide PK Parameter CLast</title>
        <description>Pyrazinamide PK parameter CLast obtained Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Pyrazinamide PK Parameter CLast</title>
          <description>Pyrazinamide PK parameter CLast obtained Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PZA CLast at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3370" lower_limit="2320" upper_limit="5470"/>
                    <measurement group_id="O2" value="2850" lower_limit="1500" upper_limit="5050"/>
                    <measurement group_id="O3" value="3130" lower_limit="2570" upper_limit="3460"/>
                    <measurement group_id="O4" value="2710" lower_limit="1930" upper_limit="3830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PZA CLast at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1955.0" lower_limit="997.5" upper_limit="2735.0"/>
                    <measurement group_id="O2" value="1280" lower_limit="909" upper_limit="3050"/>
                    <measurement group_id="O3" value="1790" lower_limit="1450" upper_limit="2900"/>
                    <measurement group_id="O4" value="1770" lower_limit="1270" upper_limit="2150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24hour for Ethambutol (EMB)</title>
        <description>PK AUCs of Ethambutol (EMB) from 0 to 24 hours obtained at Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24hour for Ethambutol (EMB)</title>
          <description>PK AUCs of Ethambutol (EMB) from 0 to 24 hours obtained at Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
          <units>h*ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EMB AUC0-24hour at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11918.8" lower_limit="9783.4" upper_limit="12803.2"/>
                    <measurement group_id="O2" value="11145.8" lower_limit="9336.6" upper_limit="14125.3"/>
                    <measurement group_id="O3" value="11322.4" lower_limit="9549.6" upper_limit="13937.0"/>
                    <measurement group_id="O4" value="10716.8" lower_limit="9381.2" upper_limit="13678.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EMB AUC0-24hour at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16414.9" lower_limit="13813.1" upper_limit="19637.1"/>
                    <measurement group_id="O2" value="16675.9" lower_limit="12589.8" upper_limit="18585.1"/>
                    <measurement group_id="O3" value="15181.2" lower_limit="14074.7" upper_limit="17338.1"/>
                    <measurement group_id="O4" value="16574.6" lower_limit="13314.9" upper_limit="17422.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ethambutol PK Parameter CL/F</title>
        <description>Ethambutol PK parameter CL/F obtained Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Ethambutol PK Parameter CL/F</title>
          <description>Ethambutol PK parameter CL/F obtained Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
          <units>L/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EMB CL/F Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6" lower_limit="68.7" upper_limit="105.0"/>
                    <measurement group_id="O2" value="85.4" lower_limit="73.9" upper_limit="97.1"/>
                    <measurement group_id="O3" value="83.8" lower_limit="65.4" upper_limit="106.0"/>
                    <measurement group_id="O4" value="76.5" lower_limit="73.9" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EMB CL/F Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" lower_limit="51.0" upper_limit="65.9"/>
                    <measurement group_id="O2" value="63.5" lower_limit="53.5" upper_limit="72.0"/>
                    <measurement group_id="O3" value="56.8" lower_limit="47.1" upper_limit="75.2"/>
                    <measurement group_id="O4" value="60.1" lower_limit="52.4" upper_limit="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ethambutol PK Parameter Cmax</title>
        <description>Ethambutol PK parameter Cmax obtained Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Ethambutol PK Parameter Cmax</title>
          <description>Ethambutol PK parameter Cmax obtained Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EMB Cmax at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2650" lower_limit="1745" upper_limit="2960"/>
                    <measurement group_id="O2" value="2040" lower_limit="1840" upper_limit="2460"/>
                    <measurement group_id="O3" value="2470" lower_limit="1790" upper_limit="3460"/>
                    <measurement group_id="O4" value="2220" lower_limit="1900" upper_limit="2680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EMB Cmax at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2980" lower_limit="2220" upper_limit="3525"/>
                    <measurement group_id="O2" value="3090" lower_limit="2270" upper_limit="3370"/>
                    <measurement group_id="O3" value="2780" lower_limit="2580" upper_limit="3220"/>
                    <measurement group_id="O4" value="2920" lower_limit="2530" upper_limit="3250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ethambutol PK Parameter CLast</title>
        <description>Ethambutol PK parameter CLast obtained Day 1 and Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RHZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 14.</description>
          </group>
          <group group_id="O2">
            <title>RHZE-RZE</title>
            <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O3">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
          <group group_id="O4">
            <title>RZE-RZE</title>
            <description>Participants were administered only RZE from Day 1 through Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Ethambutol PK Parameter CLast</title>
          <description>Ethambutol PK parameter CLast obtained Day 1 and Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EMB CLast at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="40.0" upper_limit="106.5"/>
                    <measurement group_id="O2" value="85" lower_limit="40" upper_limit="107"/>
                    <measurement group_id="O3" value="40" lower_limit="40" upper_limit="94"/>
                    <measurement group_id="O4" value="86" lower_limit="40" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EMB CLast at Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.0" lower_limit="167.0" upper_limit="235.5"/>
                    <measurement group_id="O2" value="176" lower_limit="159" upper_limit="208"/>
                    <measurement group_id="O3" value="164" lower_limit="136" upper_limit="199"/>
                    <measurement group_id="O4" value="159" lower_limit="134" upper_limit="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24hour for Moxifloxacin (Mox) at Day 14</title>
        <description>PK AUCs of Moxiflozacin (Mox) from 0 to 24 hours obtained at Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. Only the participants in the RHZE-RMZE arm received Mox from Day 3 through Day 14</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24hour for Moxifloxacin (Mox) at Day 14</title>
          <description>PK AUCs of Moxiflozacin (Mox) from 0 to 24 hours obtained at Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. Only the participants in the RHZE-RMZE arm received Mox from Day 3 through Day 14</population>
          <units>h*ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22498.4" lower_limit="21012.8" upper_limit="23318.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moxifloxacin PK Parameter CL/F at Day 14</title>
        <description>Moxifloxacin PK parameter CL/F obtained Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. Only the participants in the RHZE-RMZE arm received Mox from Day 3 through Day 14</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Moxifloxacin PK Parameter CL/F at Day 14</title>
          <description>Moxifloxacin PK parameter CL/F obtained Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. Only the participants in the RHZE-RMZE arm received Mox from Day 3 through Day 14</population>
          <units>L/hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="17.2" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moxifloxacin PK Parameter Cmax at Day 14</title>
        <description>Moxifloxacin PK parameter Cmax obtained Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. Only the participants in the RHZE-RMZE arm received Mox from Day 3 through Day 14</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Moxifloxacin PK Parameter Cmax at Day 14</title>
          <description>Moxifloxacin PK parameter Cmax obtained Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. Only the participants in the RHZE-RMZE arm received Mox from Day 3 through Day 14</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3010" lower_limit="2710" upper_limit="3500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moxifloxacin PK Parameter CLast at Day 14</title>
        <description>Moxifloxacin PK parameter CLast obtained Day 14</description>
        <time_frame>-0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14</time_frame>
        <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. Only the participants in the RHZE-RMZE arm received Mox from Day 3 through Day 14.</population>
        <group_list>
          <group group_id="O1">
            <title>RHZE-RMZE</title>
            <description>Participants will be administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Moxifloxacin PK Parameter CLast at Day 14</title>
          <description>Moxifloxacin PK parameter CLast obtained Day 14</description>
          <population>63 with qualified samples were included in the primary and secondary analyses including PK analysis. Only the participants in the RHZE-RMZE arm received Mox from Day 3 through Day 14.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178" lower_limit="150" upper_limit="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From treatment dispensation to study discontinuation. The duration of the study was 29 days.</time_frame>
      <desc>The protocol required reporting of all new diagnoses and new signs and symptoms and laboratory abnormalities of &gt;=Grade 2. The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs. Expedited adverse event reporting followed Version 2.0 of the DAIDS Expedited Adverse Event Manual.</desc>
      <group_list>
        <group group_id="E1">
          <title>RHZE-RHZE</title>
          <description>Participants were administered RHZE from Day 1 to Day 14.</description>
        </group>
        <group group_id="E2">
          <title>RHZE-RZE</title>
          <description>Participants were administered RHZE from Day 1 to Day 2, then RZE from Day 3 to Day 14.</description>
        </group>
        <group group_id="E3">
          <title>RHZE-RMZE</title>
          <description>Participants were administered RHZE Day 1 to Day 2 and RMZE from Day 3 to Day 14.</description>
        </group>
        <group group_id="E4">
          <title>RZE-RZE</title>
          <description>Participants were administered only RZE from Day 1 through Day 14.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social &amp; Scientific Systems, Inc.</organization>
      <phone>(301) 628-3313</phone>
      <email>ACTGCT.Gov@s-3.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

